Get the Stockscreener App
0.8904
4.50%
0.032
Lineage Cell Therapeutics Inc Stock (LCTX) Forecast
The Lineage Cell Therapeutics Inc (LCTX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $1.1454, representing a +28.63% increase from the current price of $0.8904. The highest analyst price target is $1.2503, and the lowest is $1.0404.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month LCTX Price Target
Average 2.1986
(+146.93% Upside)
Is Lineage Cell Therapeutics Inc (LCTX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 75.80 | Sell |
| STOCH(9,6) | 71.66 | Neutral |
| STOCHRSI(14) | 97.71 | Sell |
| MACD(12,26) | 0.0822 | Buy |
| ADX(14) | 59.97 | Buy |
| William %R | -3.2083 | Sell |
| CCI(14) | 103.22 | Buy |
Buy: 3
Sell: 3
Neutral: 1
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.7605
Buy
|
0.7787
Buy
|
| MA20 |
0.7053
Buy
|
0.7101
Buy
|
| MA50 |
0.5555
Buy
|
0.6157
Buy
|
| MA100 |
0.563
Buy
|
0.5983
Buy
|
| MA200 |
0.6543
Buy
|
0.6746
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, LCTX could be considered a Strong Buy, with 17 technical analysis indicators signaling 13 Buy signals, 3 signaling Sell signals and 1 Neutral signals. This might be a good time to open fresh positions on LCTX, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 75.8 indicates that LCTX is overbought. This suggests that LCTX price has experienced a significant increase over a specified lookback period, potentially leading to a correction.
- STOCH (Stochastic Oscillator): The STOCH value of 71.66 indicates that LCTX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 97.71 indicates that LCTX is oversold. This suggests that LCTX price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 59.97 suggests an extremely strong trend in the market. Such high values are relatively rare and indicate a very robust directional movement.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 103.22 indicates that LCTX is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term LCTX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Lineage Cell Therapeutics Inc financial reports and earnings history, Lineage Cell Therapeutics Inc (LCTX) stock could reach $1.3661 by 2030, $2.0735 by 2040 and $2.7483 by 2050. See the projected annual prices until 2050 of the Lineage Cell Therapeutics Inc stock below:
- Lineage Cell Therapeutics Inc (LCTX) is expected to reach an average price of $1.55 in 2035, with a high prediction of $1.8395 and a low estimate of $1.53. This indicates an $74.08% rise from the last recorded price of $0.8904.
- Lineage Cell Therapeutics Inc (LCTX) stock is projected to chart a bullish course in 2040, with an average price target of $1.8635, representing an $109.29% surge from its current level. The forecast ranges from a conservative $1.677 to a sky-high $2.0735.
- Our analysts predict Lineage Cell Therapeutics Inc (LCTX) to jump 163.37% by 2045, soaring from $2.295 to an average price of $2.345, potentially reaching $2.423. While $2.295 is the low estimate, the potential upside is significant.
- Lineage Cell Therapeutics Inc (LCTX) stock is expected to climb by 2050, reaching an average of $2.53, a $184.15% jump from its current level. However, a wide range of estimates exists, with high and low targets of $2.7483 and $2.51, respectively, highlighting the market's uncertainty.
Lineage Cell Therapeutics Inc Stock (LCTX) Year by Year Forecast
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2025
Lineage Cell Therapeutics Inc Stock (LCTX) is expected to reach an average price of $2.0253 in 2025, with a high prediction of $3.2546 and a low estimate of $0.7961. This indicates an +127.46% rise from the last recorded price of $0.8904.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| July, 2025 | $1.1214 | $1.0404 | $1.2503 | +25.94% |
| August, 2025 | $1.1686 | $1.0815 | $1.3611 | +31.25% |
| September, 2025 | $1.3223 | $1.172 | $1.652 | +48.51% |
| October, 2025 | $1.6532 | $1.3225 | $1.8027 | +85.67% |
| November, 2025 | $1.9839 | $1.6125 | $2.2337 | +122.81% |
| December, 2025 | $2.4347 | $1.849 | $3.2546 | +173.44% |
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2026
The predicted value for Lineage Cell Therapeutics Inc (LCTX) in 2026 is set at an average of $2.5662. Estimates vary from a peak of $3.3568 to a trough of $1.7756, indicating an +188.21% surge from the present price of $0.8904.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $2.5254 | $2.3954 | $3.3568 | +183.63% |
| February, 2026 | $2.5961 | $1.7756 | $2.8061 | +191.56% |
| March, 2026 | $2.5268 | $2.3263 | $2.8765 | +183.78% |
| April, 2026 | $2.6876 | $2.3675 | $3.1273 | +201.85% |
| May, 2026 | $2.9283 | $2.5378 | $3.2283 | +228.88% |
| June, 2026 | $2.989 | $2.8391 | $3.2285 | +235.69% |
| July, 2026 | $2.8499 | $2.6793 | $2.9993 | +220.06% |
| August, 2026 | $3.0205 | $2.515 | $3.0205 | +239.23% |
| September, 2026 | $2.8164 | $2.4909 | $3.0307 | +216.31% |
| October, 2026 | $2.5121 | $2.5019 | $2.8066 | +182.13% |
| November, 2026 | $2.2228 | $2.2028 | $2.8423 | +149.64% |
| December, 2026 | $2.9136 | $2.0335 | $2.9236 | +227.23% |
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Lineage Cell Therapeutics Inc (LCTX) is $2.1028, with a high forecast of $2.9438 and a low forecast of $1.2618. This indicates an +136.17% increase from the last price of $0.8904.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $1.8043 | $1.8043 | $2.9438 | +102.64% |
| February, 2027 | $1.735 | $1.6395 | $1.9145 | +94.86% |
| March, 2027 | $1.5759 | $1.4909 | $1.8052 | +76.98% |
| April, 2027 | $1.8265 | $1.416 | $1.8964 | +105.14% |
| May, 2027 | $1.4572 | $1.3672 | $1.8517 | +63.66% |
| June, 2027 | $1.4881 | $1.3376 | $1.5581 | +67.12% |
| July, 2027 | $1.6088 | $1.4586 | $1.7884 | +80.68% |
| August, 2027 | $1.8594 | $1.5289 | $1.9992 | +108.83% |
| September, 2027 | $1.6903 | $1.6603 | $2.03 | +89.84% |
| October, 2027 | $1.541 | $1.521 | $1.7605 | +73.07% |
| November, 2027 | $1.4417 | $1.3417 | $1.5912 | +61.91% |
| December, 2027 | $1.5525 | $1.2618 | $1.6625 | +74.36% |
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2028
In 2028, Lineage Cell Therapeutics Inc (LCTX) is projected to reach an average price of $1.5493, with a high projection of $1.8246 and a low estimate of $1.2741. This indicates an +74.00% rise from the last price of $0.8904.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.6932 | $1.4627 | $1.753 | +90.16% |
| February, 2028 | $1.3339 | $1.3039 | $1.7436 | +49.81% |
| March, 2028 | $1.6448 | $1.2741 | $1.8246 | +84.72% |
| April, 2028 | $1.6254 | $1.5454 | $1.7449 | +82.55% |
| May, 2028 | $1.6563 | $1.4656 | $1.7261 | +86.02% |
| June, 2028 | $1.657 | $1.5865 | $1.7968 | +86.09% |
| July, 2028 | $1.6277 | $1.5373 | $1.7577 | +82.80% |
| August, 2028 | $1.6285 | $1.4882 | $1.6485 | +82.90% |
| September, 2028 | $1.6192 | $1.5592 | $1.8177 | +81.85% |
| October, 2028 | $1.7799 | $1.5894 | $1.7799 | +99.90% |
| November, 2028 | $1.5707 | $1.5706 | $1.7901 | +76.41% |
| December, 2028 | $1.4414 | $1.4364 | $1.6561 | +61.89% |
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2029
The 2029 price forecast for Lineage Cell Therapeutics Inc Stock (LCTX) is $1.4817 on average, with a high prediction of $1.8667 and a low estimate of $1.0966. This represents an +66.40% increase from the previous price of $0.8904.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.3823 | $1.3518 | $1.6219 | +55.24% |
| February, 2029 | $1.203 | $1.183 | $1.4526 | +35.10% |
| March, 2029 | $1.2937 | $1.2033 | $1.3537 | +45.29% |
| April, 2029 | $1.4543 | $1.1544 | $1.5243 | +63.34% |
| May, 2029 | $1.2352 | $1.0966 | $1.5645 | +38.72% |
| June, 2029 | $1.2959 | $1.2455 | $1.4355 | +45.54% |
| July, 2029 | $1.5266 | $1.3061 | $1.7064 | +71.45% |
| August, 2029 | $1.3974 | $1.3574 | $1.8667 | +56.94% |
| September, 2029 | $1.3403 | $1.2703 | $1.4276 | +50.53% |
| October, 2029 | $1.4871 | $1.2509 | $1.5921 | +67.01% |
| November, 2029 | $1.3875 | $1.3231 | $1.5024 | +55.83% |
| December, 2029 | $1.2098 | $1.2048 | $1.4438 | +35.87% |
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2030
Lineage Cell Therapeutics Inc Stock (LCTX) is expected to reach an average price of $1.5309 in 2030, with a high forecast of $2.1003 and a low forecast of $0.9614. This signifies an +71.93% surge from the last price of $0.8904.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $1.2115 | $1.0899 | $1.3661 | +36.06% |
| February, 2030 | $1.3192 | $0.9614 | $1.3779 | +48.16% |
| March, 2030 | $1.4692 | $1.1583 | $1.6192 | +65.01% |
| April, 2030 | $1.8856 | $1.4296 | $2.1003 | +111.77% |
| May, 2030 | $1.2618 | $1.0121 | $1.871 | +41.71% |
| June, 2030 | $1.1894 | $1.1346 | $1.3077 | +33.58% |
| July, 2030 | $1.3444 | $1.155 | $1.4751 | +50.99% |
| August, 2030 | $1.4468 | $1.2758 | $1.6368 | +62.49% |
| September, 2030 | $1.2256 | $1.2219 | $1.5271 | +37.65% |
| October, 2030 | $1.3491 | $1.1688 | $1.4124 | +51.51% |
| November, 2030 | $1.3562 | $1.2609 | $1.4705 | +52.32% |
| December, 2030 | $1.3795 | $1.2816 | $1.5823 | +54.93% |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):